Answers are grounded in this paper and cite their sources.
¹⁸F-DCFPyL was recently approved by the FDA for evaluation prior to definitive therapy and for biochemical recurrence. Here we focus on the key data that justify the clinical use of ¹⁸F-DCFPyL, as well as those aspects of protocol implementation and image interpretation that are important to the nuclear medicine physicians and radiologists who will interpret ¹⁸F-DCFPyL PET/CT and PET/MR scans.
No takes yet. Share an insight, caveat, or question.
Song et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: